CA2988930A1 - Bacteria engineered to treat diseases associated with hyperammonemia - Google Patents
Bacteria engineered to treat diseases associated with hyperammonemia Download PDFInfo
- Publication number
- CA2988930A1 CA2988930A1 CA2988930A CA2988930A CA2988930A1 CA 2988930 A1 CA2988930 A1 CA 2988930A1 CA 2988930 A CA2988930 A CA 2988930A CA 2988930 A CA2988930 A CA 2988930A CA 2988930 A1 CA2988930 A1 CA 2988930A1
- Authority
- CA
- Canada
- Prior art keywords
- genetically engineered
- gene
- bacterium
- promoter
- engineered bacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
- C12P13/10—Citrulline; Arginine; Ornithine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P7/00—Preparation of oxygen-containing organic compounds
- C12P7/62—Carboxylic acid esters
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/185—Escherichia
- C12R2001/19—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (31)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562173706P | 2015-06-10 | 2015-06-10 | |
| US201562173710P | 2015-06-10 | 2015-06-10 | |
| US62/173,706 | 2015-06-10 | ||
| US62/173,710 | 2015-06-10 | ||
| US201562183935P | 2015-06-24 | 2015-06-24 | |
| US62/183,935 | 2015-06-24 | ||
| US201562184770P | 2015-06-25 | 2015-06-25 | |
| US201562184811P | 2015-06-25 | 2015-06-25 | |
| US62/184,770 | 2015-06-25 | ||
| US62/184,811 | 2015-06-25 | ||
| US201562248805P | 2015-10-30 | 2015-10-30 | |
| US62/248,805 | 2015-10-30 | ||
| US201562256041P | 2015-11-16 | 2015-11-16 | |
| US201562256048P | 2015-11-16 | 2015-11-16 | |
| US201562256039P | 2015-11-16 | 2015-11-16 | |
| US62/256,048 | 2015-11-16 | ||
| US62/256,039 | 2015-11-16 | ||
| US62/256,041 | 2015-11-16 | ||
| US201562263329P | 2015-12-04 | 2015-12-04 | |
| US62/263,329 | 2015-12-04 | ||
| US14/960,333 | 2015-12-04 | ||
| US14/960,333 US9487764B2 (en) | 2014-12-05 | 2015-12-04 | Bacteria engineered to treat diseases associated with hyperammonemia |
| US201662277654P | 2016-01-12 | 2016-01-12 | |
| US62/277,654 | 2016-01-12 | ||
| US201662291468P | 2016-02-04 | 2016-02-04 | |
| US62/291,468 | 2016-02-04 | ||
| US201662293749P | 2016-02-10 | 2016-02-10 | |
| US62/293,749 | 2016-02-10 | ||
| PCT/US2016/020530 WO2016141108A1 (en) | 2015-03-02 | 2016-03-02 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier |
| USPCT/US16/020530 | 2016-03-02 | ||
| PCT/US2016/034200 WO2016200614A2 (en) | 2015-06-10 | 2016-05-25 | Bacteria engineered to treat diseases associated with hyperammonemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2988930A1 true CA2988930A1 (en) | 2016-12-15 |
Family
ID=57504262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2988930A Abandoned CA2988930A1 (en) | 2015-06-10 | 2016-05-25 | Bacteria engineered to treat diseases associated with hyperammonemia |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP3307879A2 (https=) |
| JP (2) | JP6817966B2 (https=) |
| AU (1) | AU2016274311A1 (https=) |
| CA (1) | CA2988930A1 (https=) |
| WO (1) | WO2016200614A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119592452A (zh) * | 2024-11-23 | 2025-03-11 | 清华大学 | 洋葱伯克霍尔德菌及其浸出废料中稀土元素的方法 |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017136795A1 (en) | 2016-02-04 | 2017-08-10 | Synlogic, Inc. | Bacteria engineered to treat diseases associated with tryptophan metabolism |
| IL270817B2 (en) * | 2017-05-24 | 2025-10-01 | Thoeris Gmbh | Use of glutamine synthetase to treat hyperammonemia |
| JP7460531B2 (ja) | 2017-12-05 | 2024-04-02 | バイオピーエルエックス,インコーポレイティド | 微生物感染を防ぐための方法および組成物 |
| CN110446259B (zh) * | 2018-05-04 | 2022-04-15 | 大唐移动通信设备有限公司 | 一种寻呼机会的位置确定方法及通信设备 |
| WO2020223345A1 (en) | 2019-04-29 | 2020-11-05 | Antipov Eugene | Enumeration of genetically engineered microorganisms by live cell counting techniques |
| WO2020239882A1 (en) | 2019-05-30 | 2020-12-03 | Recordati Industria Chimica E Farmaceutica S.P.A. | Pharmaceutical formulation for carglumic acid |
| AU2020288624B2 (en) | 2019-06-04 | 2025-09-25 | Cocoon Biotech Inc. | Silk-based products, formulations, and methods of use |
| WO2021107500A1 (ko) * | 2019-11-29 | 2021-06-03 | 주식회사 지니스 | 혈중 암모니아 수치 저하능을 갖는 균주 및 이를 포함하는 신경세포 보호용 조성물 |
| EP3839051A1 (en) * | 2019-12-19 | 2021-06-23 | Evonik Operations GmbH | Method for the fermentative production of guanidinoacetic acid |
| WO2022120028A2 (en) | 2020-12-02 | 2022-06-09 | Synlogic Operating Company, Inc. | Engineered microorganisms |
| WO2022210867A1 (ja) | 2021-03-31 | 2022-10-06 | 日本製鉄株式会社 | 無方向性電磁鋼板、無方向性電磁鋼板の打ち抜き方法および無方向性電磁鋼板の打ち抜き用金型 |
| CN120000813A (zh) * | 2025-02-17 | 2025-05-16 | 温州医科大学 | 工程益生菌在防治阿尔茨海默病中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3083315B2 (ja) * | 1990-10-29 | 2000-09-04 | 株式会社ヤクルト本社 | 血中アンモニア低下剤 |
| GB9107305D0 (en) | 1991-04-08 | 1991-05-22 | Unilever Plc | Probiotic |
| IT1290679B1 (it) * | 1997-02-14 | 1998-12-10 | Alfa Wassermann Spa | Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi. |
| US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6203797B1 (en) | 1998-01-06 | 2001-03-20 | Stephen C. Perry | Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome |
| EP1135461A4 (en) | 1998-12-02 | 2003-03-26 | Univ Boston | GEN NETWORKS FOR CONTROLLING GENE EXPRESSION |
| EP1034787A1 (en) | 1999-03-11 | 2000-09-13 | Société des Produits Nestlé S.A. | Lactobacillus strains preventing diarrhea caused by pathogenic bacteria |
| US7731976B2 (en) | 2003-08-29 | 2010-06-08 | Cobb And Company, Llp | Treatment of irritable bowel syndrome using probiotic composition |
| WO2009123029A1 (ja) * | 2008-03-31 | 2009-10-08 | 株式会社 大塚製薬工場 | 血中アンモニア調整剤 |
| AU2014331610B2 (en) * | 2013-10-03 | 2019-11-07 | Trustees Of The University Of Pennsylvania | Compositions comprising a defined microbiome and methods of use thereof |
-
2016
- 2016-05-25 AU AU2016274311A patent/AU2016274311A1/en not_active Abandoned
- 2016-05-25 CA CA2988930A patent/CA2988930A1/en not_active Abandoned
- 2016-05-25 JP JP2017564379A patent/JP6817966B2/ja not_active Expired - Fee Related
- 2016-05-25 EP EP16731402.0A patent/EP3307879A2/en not_active Withdrawn
- 2016-05-25 WO PCT/US2016/034200 patent/WO2016200614A2/en not_active Ceased
-
2020
- 2020-12-25 JP JP2020217391A patent/JP2021061846A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119592452A (zh) * | 2024-11-23 | 2025-03-11 | 清华大学 | 洋葱伯克霍尔德菌及其浸出废料中稀土元素的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016200614A2 (en) | 2016-12-15 |
| JP2018523978A (ja) | 2018-08-30 |
| JP6817966B2 (ja) | 2021-01-20 |
| JP2021061846A (ja) | 2021-04-22 |
| EP3307879A2 (en) | 2018-04-18 |
| AU2016274311A1 (en) | 2018-01-18 |
| WO2016200614A3 (en) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11845964B2 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| US12409195B2 (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
| US20240076645A1 (en) | Bacteria engineered to reduce hyperphenylalaninemia | |
| CA2988930A1 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| US20170232043A1 (en) | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid | |
| WO2016090343A1 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| WO2017139697A1 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| EP3227440B1 (en) | Bacteria engineered to treat diseases associated with hyperammonemia | |
| AU2021220882A1 (en) | Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof | |
| EP3328988A1 (en) | Bacteria engineered to treat disorders involving propionate catabolism | |
| US20220168362A1 (en) | Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20210525 |
|
| FZDE | Discontinued |
Effective date: 20230927 |